 DR Reports --
April 2004
 In This Issue...
Sleep disorders, particularly
insomnia, are very common. Other less common sleep disorders include sleep
apnea, restless legs syndrome, and narcolepsy--all of which result in
sleep deprivation, the economic burden of which is estimated to exceed $100
billion in the United States. The growing sleep disorders market will reach
more than $3 billion in 2008, by which time new players will have entered and
will be enjoying a degree of success. Pfizer and Neurocrine will jointly launch
a new product and Sepracor is expected to bring its single-enantiomer product
to market, but other companies will see their market share erode significantly.
Compared with many other central nervous system indications, the
pipeline of emerging therapies for sleep disorders is relatively sparse, but
established players such as GlaxoSmithKline are developing new products that
may expand this market.
In this report on the sleep
disorders market, we focus on therapies being developed for insomnia, sleep
apnea, restless legs syndrome, and narcolepsy. We identify the major and
emerging companies in the sleep disorders marketplace and assess their marketed
and pipeline drugs in terms of clinical potential and commercial viability.
Additionally, we forecast market share by company for the major and emerging
players to 2008. We describe the etiology and pathophysiology of these
diseases, their epidemiology, and their diagnosis. We discuss the current
therapies used to treat these disorders and evaluate the clinical and
commercial potential of emerging agents. We conclude with a series of detailed
company profiles, including companies' alliance activity and financial
information, and we note trends in the growth of companies'
pharmaceutical sales and R&D expenses.
|
